Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Withdrawn

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Compassionate Single Subject Use of FG-3019 in Locally Advanced, Unresectable Pancreatic Cancer (Emergency Use of a Test Article)

Outcome
Stopped earlyThe patient passed before treatment could be started (Other)
Phase
No phase (not a drug trial)
Status
Withdrawn
Study type
Interventional
Planned start
August 2016
Planned end
August 2017
Enrollment
0 participants
Sites
0
Primary outcomes
FG-3019 treatment regimen to increase OS (overall survival)
Sponsor type
Academic / other
Results posted
No
Last update
7 October 2016

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Single compassionate use subject is an 83 year old woman with a history of lymph node positive breast cancer and recently diagnosed pancreatic cancer in May. With an Eastern Cooperative Oncology Group (ECOG) of 2, it is felt that she cannot tolerate more aggressive chemotherapy. The investigators propose to administer FG-3019 on a compassionate pleas basis in combination with gemzar. The patient is currently being treated and is tolerating gemzar.

Detailed description public domain (ClinicalTrials.gov)

The FG-3019 treatment will be administered over a 28-day cycle: * Dose: 35 mg/kg * Route: IV over one hour following completion of gemcitabine infusion * Schedule: * Days 1, 8, and 15 * Please note that Day 8 infusion will on be completed during the first treatment cycle On Drug Evaluation The patient will be seen prior to every FG-3019 treatment by the treating physician. The following procedures will be conducted at each visit: * History and thorough symptom assessment * Physical examination * Laboratory assessments (these can be collected up to 3 days prior to treatment): * Complete blood count (CBC) and differential * Comprehensive Metabolic Panel (Chemistry): bicarbonate, blood, urea, nitrogen (BUN), calcium, creatinine, glucose, potassium, sodium * Liver Function Tests: Alkaline phosphatase (ALP), Alanine transaminase (ALT), Aspartate transaminase (AST), total bilirubin * Carbohydrate antigen (CA) 19-9 ECGs will be conducted during the screening and end of treatment visits. CT scans of the chest and abdomen will be done every 12 to 16 weeks. All of these data will be recorded and stored with their source documents.